Research report: Adjuvant T-DM1 versus trastuzumab plus pertuzumab for residual disease after neoadjuvant dual HER2 blockade in HER2-positive early breast cancer: a multicenter real-world study
A multicenter Chinese real-world cohort found that adjuvant T-DM1 was associated with better early invasive disease-free survival than trastuzumab plus ...
